Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00302900 · ClinicalTrials.gov registry record · Phase 2

Preventing Negative Reactions in First Time Blood Donors to Encourage Subsequent Blood Donations

A Phase 2 study, sponsored by Ohio University.

Completed
Registry status
Phase 2
Development phase
441
Enrollment target

NCT00302900: Completed Phase 2 study, sponsored by Ohio University.

NCT00302900 is a Phase 2 study that has completed, run by Ohio University. The registered enrollment target is 441 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (232% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00302900, a Phase 2 study, has completed, sponsored by Ohio University.

COMPLETED
Registry status
Phase 2
Development phase
441 participants
Enrollment target

Study Summary

Many individuals experience negative reactions when donating blood, including dizziness, lightheadedness, or fainting. Such reactions may discourage them from donating again. This study will evaluate the effectiveness of pre-donation water consumption and a muscle tensing exercise during donation to reduce negative reactions among new blood donors. This study will also evaluate whether reducing negative reactions increases the likelihood of donors returning to give blood in the future.

Interventions

  • BEHAVIORAL Pre-Donation Water Consumption
  • BEHAVIORAL Muscle Tensing Exercise During Donation
  • BEHAVIORAL Muscle Tensing Exercise Prior to Donation

Trial Details

FieldValue
Enrollment Target 441 participants
Start Date 2006-01
Est. Completion 2010-03
Phase Phase 2
Ohio University

51 total trials

What the finished NCT00302900 record still lists

NCT00302900 is an interventional study that assigns participants to a tested intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (232% higher).

The record links to 0 conditions, and to 3 interventions - of which Pre-Donation Water Consumption is the first listed.

NCT00302900 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00302900 about?

NCT00302900 is a clinical study titled "Preventing Negative Reactions in First Time Blood Donors to Encourage Subsequent Blood Donations". Many individuals experience negative reactions when donating blood, including dizziness, lightheadedness, or fainting. Such reactions may discourage them from donating again. This study will evaluate the effectiveness of pre-donation water consumption and a muscle tensing exercise during donation to...

What is the current status of trial NCT00302900?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 441 participants. The study started on 2006-01. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00302900?

The interventions under investigation include: Pre-Donation Water Consumption (BEHAVIORAL), Muscle Tensing Exercise During Donation (BEHAVIORAL), Muscle Tensing Exercise Prior to Donation (BEHAVIORAL).

Who is sponsoring clinical trial NCT00302900?

This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00302900's enrollment target sits among peer trials

441 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02679144 · 441 participants · Phase 2

    Neuroblastoma Maintenance Therapy Trial

  • NCT03704766 · 442 participants · NA

    Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis

  • NCT04657068 · 442 participants · Phase 1

    A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • NCT05410145 · 442 participants · Phase 1

    A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00302900, the US trial registry maintained by the National Library of Medicine. NCT00302900 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.